Congenital adrenal hyperplasia in adolescence — a gynecological perspective
, 3, 3, 3, 3, 3, 4, 3
Abstract
Objectives: Analysis of congenital adrenal hyperplasia (CAH) cases, gynaecological implications, referral reasons to gynaecologist and treatment.
Material and methods: Retrospective, longitudinal, single-centre study with female CAH paediatric patients ≥ 10 years-old, followed between 1998–2018 in gynaecology and endocrinology departments at a public university tertiary hospital.
Results: 47 patients, 34.0% (n = 16) with classic, 66.0% (n = 31) with non-classic forms (NCAH), CYP21 deficit and 46,XX karyotype. We found a normal median menarche age (11.5 IQR 2 [6–15] years-old), but significantly earlier in NCAH (p = 0.003). Precocious puberty occurred in 48.9%, n = 23. Primary amenorrhea occurred in salt-wasting form (21.4%, n = 3). Oligomenorrhea and hirsutism were significantly more prevalent in NCAH (p = 0.018, p = 0.014 respectively) and acanthosis nigricans and virilization signs in classic forms (p = 0.05, p = 0.000 respectively). Sixteen patients (34.0%) were referred to gynaecology, mostly due to menstrual irregularities (50.0%, n = 8). Medical treatment with isolated or combined corticoids, oestrogen and progestogen were chosen in all but one case. Gonadotropin-releasing hormone analogues were used in 19.0% (n = 9). Surgery was performed in 34.0% (n = 16) patients, median age 2.0 IQR 2.5 (0.6–90) years-old.
Conclusions: This paper highlights the importance of a multidisciplinary approach. Early treatment contributes to a phenotypical feminine differentiation and normalization of the hypothalamus-pituitary-ovarian axis, which is essential given the gynaecologic and obstetric consequences of untreated cases.
Keywords: congenital adrenal hyperplasiahyperandrogenismsteroid 21-hydroxylasemenstruation disordersamenorrhea
References
- MccCann-Crosby B, Placencia Fx, Adeyemi-Fowode O, et al. Challenges in Prenatal Treatment with Dexamethasone. Pediatr Endocrinol Rev. 2018; 16(1): 186–193.
- Carmina E, Dewailly D, Escobar-Morreale HF, et al. Non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency revisited: an update with a special focus on adolescent and adult women. Hum Reprod Update. 2017; 23(5): 580–599.
- Witchel S. Congenital Adrenal Hyperplasia. Journal of Pediatric and Adolescent Gynecology. 2017; 30(5): 520–534.
- Sarafoglou K, Banks K, Kyllo J, et al. Cases of congenital adrenal hyperplasia missed by newborn screening in Minnesota. JAMA. 2012; 307(22): 2371–2374.
- Falhammar H, Frisén L, Hirschberg AL, et al. Increased risk of autoimmune disorders in 21-hydroxylase deficiency: a swedish population-based national cohort study. J Endocr Soc. 2019; 3(5): 1039–1052.
- Trinh L, Nimkarn S, New MI, et al. Growth and pubertal characteristics in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Pediatr Endocrinol Metab. 2007; 20(8): 883–891.
- Segev-Becker A, Jacobson R, Stein R, et al. Women with nonclassic congenital adrenal hyperplasia have gender, sexuality, and quality-of-life features similar to those of nonaffected women. Endocr Pract. 2020; 26(5): 535–542.
- Moran C, Azziz R, Carmina E, et al. 21-Hydroxylase-deficient nonclassic adrenal hyperplasia is a progressive disorder: a multicenter study. Am J Obstet Gynecol. 2000; 183(6): 1468–1474.
- Lause M, Kamboj A, Fernandez Faith E. Dermatologic manifestations of endocrine disorders. Transl Pediatr. 2017; 6(4): 300–312.
- Merke D, Poppas D. Management of adolescents with congenital adrenal hyperplasia. The Lancet Diabetes & Endocrinology. 2013; 1(4): 341–352.
- Kurtoğlu S, Hatipoğlu N. Non-Classical congenital adrenal hyperplasia in childhood. J Clin Res Pediatr Endocrinol. 2017; 9(1): 1–7.
- Witchel SF. Non-classic congenital adrenal hyperplasia. Steroids. 2013; 78(8): 747–750.
- Carmina E. Pathogenesis and treatment of hirsutism in late-onset congenital adrenal hyperplasia. Reproductive Medicine Review. 2009; 4(3): 179–187.
- Pall M, Azziz R, Beires J, et al. The phenotype of hirsute women: a comparison of polycystic ovary syndrome and 21-hydroxylase-deficient nonclassic adrenal hyperplasia. Fertil Steril. 2010; 94(2): 684–689.
- Carr BR, Parker CR, Madden JD, et al. Plasma levels of adrenocorticotropin and cortisol in women receiving oral contraceptive steroid treatment. J Clin Endocrinol Metab. 1979; 49(3): 346–349.
- Consensus statement on 21-hydroxylase deficiency from The Lawson Wilkins Pediatric Endocrine Society and The European Society for Paediatric Endocrinology. The Journal of Clinical Endocrinology & Metabolism. 2002; 87(9): 4048–4053.
- Merke DP, Bornstein SR. Congenital adrenal hyperplasia. The Lancet. 2005; 365(9477): 2125–2136.
- Nordenström A, Falhammar H. MANAGEMENT OF ENDOCRINE DISEASE: diagnosis and management of the patient with non-classic CAH due to 21-hydroxylase deficiency. Eur J Endocrinol. 2019; 180(3): R127–R145.
- Speiser PW, Auchus RJ, Merke DP, et al. Endocrine Society. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010; 95(9): 4133–4160.
- Wild RA, Umstot ES, Andersen RN, et al. Adrenal function in hirsutism. II. Effect of an oral contraceptive. J Clin Endocrinol Metab. 1982; 54(4): 676–681.
- Spritzer P, Billaud L, Thalabard JC, et al. Cyproterone acetate versus hydrocortisone treatment in late-onset adrenal hyperplasia. J Clin Endocrinol Metab. 1990; 70(3): 642–646.
- Stikkelbroeck N, Beerendonk C, Willemsen W, et al. The long term outcome of feminizing genital surgery for congenital adrenal hyperplasia: anatomical, functional and cosmetic outcomes, psychosexual development, and satisfaction in adult female patients. Journal of Pediatric and Adolescent Gynecology. 2003; 16(5): 289–296.
- Hagenfeldt K, Janson PO, Holmdahl G, et al. Metabolic profile and body composition in adult women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab. 2007; 92(1): 110–116.
